<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775225</url>
  </required_header>
  <id_info>
    <org_study_id>3012020</org_study_id>
    <nct_id>NCT04775225</nct_id>
  </id_info>
  <brief_title>Hip Denervation in Juvenile Idiopathic Arthritis With Hip Arthritis</brief_title>
  <official_title>Hip Denervation in Juvenile Idiopathic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients having juvenile idiopathic arthritis (according to ILAR criteria) with hip arthritis&#xD;
      were divided into two groups. Group 1 received hip denervation and group 2 controlled and&#xD;
      received a subcutaneous injection of saline. Outcome measures included pain, tenderness,&#xD;
      range of motion, range of motion, HARISS score. These outcomes were measured at baseline, 2&#xD;
      weeks, and 12 weeks&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to test the effect of denervation of the active hip in JIA and&#xD;
      comparing it with placebo without changing systemic treatment during the study. Outcome&#xD;
      measures included pain, range of motion, functional score.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2021</start_date>
  <completion_date type="Actual">April 6, 2021</completion_date>
  <primary_completion_date type="Actual">April 6, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in visual analogue scale</measure>
    <time_frame>Baseline, 2 weeks and 16 weeks</time_frame>
    <description>a scale from 0-100 will be used 0 means no pain 100 means the maximum pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in range of motion</measure>
    <time_frame>Baseline, 2 weeks and 16 weeks</time_frame>
    <description>flexion, internal rotation, external rotation range will be calculated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Harris functional score</measure>
    <time_frame>Baseline, 2 weeks and 16 weeks</time_frame>
    <description>100 means best results and 0 means worst results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>semiquantitative tenderness score</measure>
    <time_frame>Baseline, 2 weeks and 12 weeks</time_frame>
    <description>0 means no tenderness and 3 means maximum tenderness</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <condition>Hip Arthritis</condition>
  <arm_group>
    <arm_group_label>Hip denervation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive Lidocaine 2% block of the femoral and obturator genicular branches.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>this group will receive saline injection subcutaneously at the same places.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>denervation of the obturator and femoral genicular branches by Lidocaine 2 %</description>
    <arm_group_label>Hip denervation group</arm_group_label>
    <other_name>The active group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>an equivalent amount of saline will be injected subcutaneously in 2 points similar to the active group</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>The control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with JIA with unilateral hip arthritis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hip involvement due to other causes including&#xD;
&#xD;
          -  septic arthritis&#xD;
&#xD;
          -  other connective tissue diseases&#xD;
&#xD;
          -  Avascular necrosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ahmed Elsaman</name>
      <address>
        <city>Sohag</city>
        <zip>82749</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Ahmed Mahrous</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

